Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Schizophrenia Drug Market

ID: MRFR/Pharma/41802-HCR
200 Pages
Rahul Gotadki
Last Updated: April 15, 2026

Schizophrenia Drug Market Research Report: Size, Share, Trend Analysis By Drug Class (Atypical Antipsychotics, Typical Antipsychotics, Antidepressants, Mood Stabilizers), By Route of Administration (Oral, Injectable, Transdermal), By End Users (Hospitals, Clinics, Homecare), By Prescription Type (Generic Drugs, Branded Drugs) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Schizophrenia Drug Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Drug Class (USD Billion) | |
      1. 4.1.1 Atypical Antipsychotics | |
      2. 4.1.2 Typical Antipsychotics | |
      3. 4.1.3 Antidepressants | |
      4. 4.1.4 Mood Stabilizers |
    2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.2.1 Oral | |
      2. 4.2.2 Injectable | |
      3. 4.2.3 Transdermal |
    3. 4.3 Healthcare, BY End User (USD Billion) | |
      1. 4.3.1 Hospitals | |
      2. 4.3.2 Clinics | |
      3. 4.3.3 Homecare |
    4. 4.4 Healthcare, BY Prescription Type (USD Billion) | |
      1. 4.4.1 Generic Drugs | |
      2. 4.4.2 Branded Drugs |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Johnson & Johnson (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Roche (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Pfizer (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Eli Lilly and Company (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 AstraZeneca (GB) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Novartis (CH) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Otsuka Pharmaceutical (JP) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Bristol-Myers Squibb (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Sanofi (FR) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DRUG CLASS |
    7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    8. 6.5 US MARKET ANALYSIS BY END USER |
    9. 6.6 US MARKET ANALYSIS BY PRESCRIPTION TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY DRUG CLASS |
    11. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    12. 6.9 CANADA MARKET ANALYSIS BY END USER |
    13. 6.10 CANADA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY DRUG CLASS |
    16. 6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    17. 6.14 GERMANY MARKET ANALYSIS BY END USER |
    18. 6.15 GERMANY MARKET ANALYSIS BY PRESCRIPTION TYPE |
    19. 6.16 UK MARKET ANALYSIS BY DRUG CLASS |
    20. 6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    21. 6.18 UK MARKET ANALYSIS BY END USER |
    22. 6.19 UK MARKET ANALYSIS BY PRESCRIPTION TYPE |
    23. 6.20 FRANCE MARKET ANALYSIS BY DRUG CLASS |
    24. 6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    25. 6.22 FRANCE MARKET ANALYSIS BY END USER |
    26. 6.23 FRANCE MARKET ANALYSIS BY PRESCRIPTION TYPE |
    27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
    28. 6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    29. 6.26 RUSSIA MARKET ANALYSIS BY END USER |
    30. 6.27 RUSSIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    31. 6.28 ITALY MARKET ANALYSIS BY DRUG CLASS |
    32. 6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    33. 6.30 ITALY MARKET ANALYSIS BY END USER |
    34. 6.31 ITALY MARKET ANALYSIS BY PRESCRIPTION TYPE |
    35. 6.32 SPAIN MARKET ANALYSIS BY DRUG CLASS |
    36. 6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    37. 6.34 SPAIN MARKET ANALYSIS BY END USER |
    38. 6.35 SPAIN MARKET ANALYSIS BY PRESCRIPTION TYPE |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PRESCRIPTION TYPE |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY DRUG CLASS |
    45. 6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    46. 6.43 CHINA MARKET ANALYSIS BY END USER |
    47. 6.44 CHINA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    48. 6.45 INDIA MARKET ANALYSIS BY DRUG CLASS |
    49. 6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    50. 6.47 INDIA MARKET ANALYSIS BY END USER |
    51. 6.48 INDIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    52. 6.49 JAPAN MARKET ANALYSIS BY DRUG CLASS |
    53. 6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    54. 6.51 JAPAN MARKET ANALYSIS BY END USER |
    55. 6.52 JAPAN MARKET ANALYSIS BY PRESCRIPTION TYPE |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY END USER |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    64. 6.61 THAILAND MARKET ANALYSIS BY DRUG CLASS |
    65. 6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    66. 6.63 THAILAND MARKET ANALYSIS BY END USER |
    67. 6.64 THAILAND MARKET ANALYSIS BY PRESCRIPTION TYPE |
    68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
    69. 6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    70. 6.67 INDONESIA MARKET ANALYSIS BY END USER |
    71. 6.68 INDONESIA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY END USER |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY PRESCRIPTION TYPE |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
    78. 6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    79. 6.76 BRAZIL MARKET ANALYSIS BY END USER |
    80. 6.77 BRAZIL MARKET ANALYSIS BY PRESCRIPTION TYPE |
    81. 6.78 MEXICO MARKET ANALYSIS BY DRUG CLASS |
    82. 6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    83. 6.80 MEXICO MARKET ANALYSIS BY END USER |
    84. 6.81 MEXICO MARKET ANALYSIS BY PRESCRIPTION TYPE |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY END USER |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PRESCRIPTION TYPE |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY END USER |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY PRESCRIPTION TYPE |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY PRESCRIPTION TYPE, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END USER, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY PRESCRIPTION TYPE, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Drug Class (USD Billion, 2025-2035)

  • Atypical Antipsychotics
  • Typical Antipsychotics
  • Antidepressants
  • Mood Stabilizers

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Injectable
  • Transdermal

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Homecare

Healthcare By Prescription Type (USD Billion, 2025-2035)

  • Generic Drugs
  • Branded Drugs

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions